Related Experiment Video
Updated: Aug 30, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Menstrual cycle-related variations in insulin requirements and glycemic control during automated insulin delivery in
Nora Struckmeyer1,2, Sarah Landsberg1, Torben Biester1
1Centre for Diabetology and Endocrinology, Children`s Hospital AUF DER BULT, Hannover, Germany.
Objectives:
Data on menstrual cycle-related metabolic variability in adolescents with type 1 diabetes (T1D) using automated insulin delivery (AID) systems are scarce. We aimed to quantify cycle-dependent differences in insulin requirements and glycemic outcomes in this population.
Methods:
In this retrospective observational cohort study, adolescents with T1D aged 12.0-17.9 years who were at least 1 year postmenarche and had used AID for ≥6 months were included. Menstrual cycles were tracked using smartphone applications, and nine complete cycles per participant were analyzed. Insulin delivery and continuous glucose monitoring data were extracted from Glooko. Outcomes included total daily insulin dose (TDD), time in range (TIR), time above range (TAR), time below range (TBR), mean glucose, glucose coefficient of variation (CV), and recorded carbohydrate intake. Linear mixed-effects models were used.
Results:
Fifty-one adolescents contributed 459 menstrual cycles. Mean age was 14.7 ± 1.8 years, and median HbA1c was 7.2 % (interquartile range 6.8-7.5 %). TDD was higher during the luteal than the follicular phase (1.05 vs. 0.95 U/kg/day; mean difference +0.10 U/kg/day, 95 % CI 0.05-0.15; p<0.001). The luteal phase was associated with reduced TIR (-6.3 %, p=0.001), increased TAR (+5.5 %, p=0.01), higher mean glucose (+12.5 mg/dL, p=0.03), and higher CV (39.4 vs. 35.0 %, p=0.03). TBR and carbohydrate intake did not differ significantly.
Conclusions:
In adolescents with T1D who menstruate and use AID systems, insulin requirements and glycemic control vary across the menstrual cycle, with increased insulin demand and hyperglycemia during the luteal phase. These findings highlight clinically relevant cycle-related metabolic variability despite the use of AID.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Type I Diabetes III: Clinical Manifestations
Type I Diabetes I: Introduction